Effect of Salpingectomy During Conservative Hysterectomy

NCT ID: NCT01628432

Last Updated: 2018-10-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

350 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study compares the effect of bilateral salpingectomy associated with conservative hysterectomy on ovarian function to the standard hysterectomy with conservation of both ovaries and tubes in terms of hormone assays, ovarian ultrasound evaluation, complications, quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hysterectomy is one of the most common gynecologic procedures performed in clinical practice. In this study we focused on non menopausal patients under 52 years having hysterectomies for benign disease : uterine leiomyomas, adenomyosis, endometriosis, dysfunctional uterine bleeding, genital prolapse, cervical dysplasia... with failure of conservative treatment.

the standard procedure during hysterectomy with conservation of the ovaries has been the preservation of fallopian tubes with the clamps placed as close to the uterine corpus as possible. this is suggested to decrease interference with the vascular structures in the mesosalpinx and mesovarium. however it is unclear whether tubal conservation at the time of hysterectomy has any influence on ovarian blood flow or ovarian reserve. another point to be considered is the occurrence of post-hysterectomy carcinoma in the preserved fallopian tube, theoretically, these cases could be prevented if tubal excision is performed during hysterectomy The study compares the effect of bilateral salpingectomy associated with conservative hysterectomy on ovarian function to the standard hysterectomy with conservation of both ovaries and tubes in terms of hormone assays, ovarian ultrasound evaluation, complications, quality of life.

impact of treatments on ovarian reserve are tested by measuring AMH at baseline and 3 days, 6 weeks and 6, 12 months after surgeries.

quality of life is also assessed at these time points, with a questionnaire (Women Health Questionnaire WHQ).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Genital Diseases, Female Hysterotomy; Affecting Fetus Leiomyomata Uteri Adenomyosis, Endometriosis Dysfunctional Uterine Bleeding Cervical Dysplasia Uterine Prolapse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

conservative hysterectomy I

bilateral salpingectomy during hysterectomy with conservation of the ovaries

Group Type EXPERIMENTAL

conservative hysterectomy I

Intervention Type PROCEDURE

conservative hysterectomy for benign disease

conservative hysterectomy II

standard conservative hysterectomy with conservation of both ovaries and tubes

Group Type ACTIVE_COMPARATOR

Conservative hysterectomy II

Intervention Type PROCEDURE

bilateral salpingectomy during hysterectomy without conservation of the ovaries

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

conservative hysterectomy I

conservative hysterectomy for benign disease

Intervention Type PROCEDURE

Conservative hysterectomy II

bilateral salpingectomy during hysterectomy without conservation of the ovaries

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age ≥ 18 years and less than 52 years
* indication of a conservative hysterectomy for benign disease
* signed informed consent
* non menopausal women (AMH \>0,21 ng/ml)

Exclusion Criteria

* pregnancy
* desire of future pregnancy
* menopausal status
* patient unable to give informed consent
* any physical or psychiatric condition that could impair with patient's ability to cooperate with post operative data collection
* previous salpingo and /or oophorectomy (unilateral or bilateral)
* genital cancer disease or atypical endometrial hyperplasia
* hyperandrogenia
* any ovarian mass that needs surgical exploration
* any immunotherapy that could interfere with immunological tests
Minimum Eligible Age

18 Years

Maximum Eligible Age

52 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Tours

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lobna OULDAMER, MD

Role: PRINCIPAL_INVESTIGATOR

CHRU de TOURS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU

Angers, , France

Site Status

CHU

Le Kremlin-Bicêtre, , France

Site Status

CHU

Lille, , France

Site Status

Hôpital Sud

Lyon, , France

Site Status

CHU

Poitiers, , France

Site Status

CHU

Rennes, , France

Site Status

CHU

Tours, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PHRN11/LO/SALPINGOVA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.